Advertisement


Mary K. Gospodarowicz, MD, on Challenges in Cancer Control

2015 European Cancer Congress

Advertisement

Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital radiation treatment worldwide, especially in low- and middle-income countries.



Related Videos

Issues in Oncology

Frederic Amant, MD, PhD, on Cancer and Pregnancy

Frederic Amant, MD, PhD, of the Katholieke Universiteit Leuven, discusses the important decisions that must be made when a woman is diagnosed with cancer while pregnant: Should treatment be delayed or the pregnancy terminated?

Issues in Oncology

Federico Cappuzzo, MD, and Tony Mok, MD, on Managing EGFR Resistance in Lung Cancer

Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.

Kidney Cancer

Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).

Gastroesophageal Cancer
Colorectal Cancer
Survivorship

Martine Frouws, MSc, PhD, on Postdiagnosis Aspirin and Improved Survival in All GI Cancers

Martine Frouws, MD, PhD Candidate, of Leiden University Medical Centre discusses her study, which showed a significant increase in overall survival among patients with GI cancers who took aspirin compared to those who did not (Abstract 2306).

Global Cancer Care

Milena Sant, MD, on The Latest Findings From the EUROCARE 5 Study

Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).

Advertisement

Advertisement




Advertisement